Posadas Edwin M, Davidson Ben, Kohn Elise C
Laboratory of Pathology, National Cancer Institute and NCI/FDA Clinical Proteomics Program Bethesda, Maryland, USA.
Curr Opin Oncol. 2004 Sep;16(5):478-84. doi: 10.1097/00001622-200409000-00012.
Epithelial ovarian cancer is the leading cause of death from gynecologic malignancies amongst American women. Emerging proteomic technologies have promise for early diagnosis and in advancing treatment directions. Application of these technologies has produced new biomarkers, diagnostic approaches, and understanding of disease biology.
Mass spectral blood and tissue analysis has yielded new putative biomarkers that require further validation and assessment of diagnostic specificity and sensitivity. Protein signature patterns derived from mass spectrometry datastreams have been modeled and are moving into validation. Tissue-based protein analysis has led to identification of tumor and stromal protein and signal activation events in ovarian cancer. Clinical trials are now ascertaining tissue samples prior to and during therapy with molecularly targeted agents to evaluate modulation of targeted signaling pathways. Finally, proteomic analysis of tissues and metastases will outline biochemical events underlying the metastatic phenotype of ovarian cancer.
Proteomic approaches are experimental technologies applied to ovarian and other cancers. Proper validation and use of findings may advance our understanding of biochemical events that have complicated successful detection and intervention. This knowledge is the first step in fulfilling the promise of personalized molecular medicine.
上皮性卵巢癌是美国女性妇科恶性肿瘤死亡的主要原因。新兴的蛋白质组学技术有望实现早期诊断并推动治疗方向的发展。这些技术的应用已产生了新的生物标志物、诊断方法，并增进了对疾病生物学的理解。
质谱血液和组织分析已产生了新的假定生物标志物，这些标志物需要进一步验证以及评估诊断特异性和敏感性。源自质谱数据流的蛋白质特征模式已被建模并正在进入验证阶段。基于组织的蛋白质分析已导致在卵巢癌中识别出肿瘤和基质蛋白以及信号激活事件。目前，临床试验正在分子靶向药物治疗之前和期间确定组织样本，以评估靶向信号通路的调节情况。最后，对组织和转移灶的蛋白质组学分析将勾勒出卵巢癌转移表型背后的生化事件。
蛋白质组学方法是应用于卵巢癌和其他癌症的实验技术。对研究结果进行适当的验证和应用可能会增进我们对那些使成功检测和干预变得复杂的生化事件的理解。这一知识是实现个性化分子医学前景的第一步。
